Symbols / ENTX Stock $1.35 +10.66% Entera Bio Ltd.
ENTX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteEntera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Ratings
Current target
$1.35
Low
$9.00
High
$9.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-27 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2026-02-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-07 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-08 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-04-04 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-03-28 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2022-09-06 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2022-07-19 | main | B. Riley Securities | — → Buy | $5 |
| 2021-06-16 | init | B. Riley Securities | — → Buy | $9 |
- Experimental osteoporosis pill gets late-breaking ENDO 2026 slot - Stock Titan hu, 28 May 2026 12
- ENTX - Finviz ue, 28 Apr 2026 10
- Entera pushes an osteoporosis pill toward Phase 3 as cash hits $20.4M - Stock Titan Fri, 08 May 2026 07
- Insider Purchase: Director at $[ENTX] Buys 10,000 Shares - Quiver Quantitative Wed, 11 Feb 2026 08
- Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners - PR Newswire Mon, 06 Apr 2026 07
- Entera Bio Ltd. Stock (ENTX) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative ue, 30 Dec 2025 08
- Fresh $10M gives Entera Bio runway for Phase 3 osteoporosis study - Stock Titan hu, 02 Apr 2026 07
- $ENTX stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Entera Bio insiders are buying more of their own shares on market - Stock Titan Wed, 11 Feb 2026 08
- Insider Purchase: Chief Executive Officer of $ENTX Buys 11,000 Shares - Quiver Quantitative ue, 30 Dec 2025 08
- Entera Bio (ENTX) grants COO 72,993 RSUs in lieu of cash bonus - Stock Titan Fri, 08 May 2026 07
- Insider Purchase: Director at $ENTX Buys 18,000 Shares - Quiver Quantitative Wed, 11 Feb 2026 08
- [EFFECT] Entera Bio Ltd. SEC Filing - Stock Titan Sun, 17 May 2026 07
- Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan Mon, 09 Feb 2026 08
- Entera Bio (ENTX) CFO receives 58,394 RSUs through A2Z Counseling Ltd. - Stock Titan Fri, 08 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.04
-76.80%
|
0.18
|
0.00
-100.00%
|
0.13
|
| Operating Revenue |
|
0.04
-76.80%
|
0.18
|
0.00
-100.00%
|
0.13
|
| Cost Of Revenue |
|
0.04
-75.58%
|
0.17
|
0.00
-100.00%
|
0.10
|
| Reconciled Cost Of Revenue |
|
0.04
-75.58%
|
0.17
|
0.00
-100.00%
|
0.10
|
| Gross Profit |
|
0.00
-100.00%
|
0.01
|
0.00
-100.00%
|
0.03
|
| Operating Expense |
|
11.53
+20.17%
|
9.59
+7.91%
|
8.89
-31.87%
|
13.05
|
| Research And Development |
|
6.00
+33.45%
|
4.50
-0.24%
|
4.51
-22.88%
|
5.85
|
| Selling General And Administration |
|
5.53
+8.44%
|
5.09
+15.01%
|
4.43
-38.92%
|
7.25
|
| General And Administrative Expense |
|
5.53
+8.44%
|
5.09
+15.01%
|
4.43
-38.92%
|
7.25
|
| Other Gand A |
|
5.53
+8.44%
|
5.09
+15.01%
|
4.43
-38.92%
|
7.25
|
| Other Operating Expenses |
|
—
|
—
|
-0.05
+3.92%
|
-0.05
|
| Total Expenses |
|
11.57
+18.48%
|
9.77
+9.84%
|
8.89
-32.39%
|
13.15
|
| Operating Income |
|
-11.53
-20.28%
|
-9.59
-7.81%
|
-8.89
+31.70%
|
-13.02
|
| Total Operating Income As Reported |
|
-11.53
-20.28%
|
-9.59
-7.81%
|
-8.89
+31.70%
|
-13.02
|
| EBITDA |
|
-11.50
-20.55%
|
-9.54
-7.97%
|
-8.84
+31.79%
|
-12.95
|
| Normalized EBITDA |
|
-11.50
-20.55%
|
-9.54
-7.97%
|
-8.84
+31.79%
|
-12.95
|
| Reconciled Depreciation |
|
0.03
-34.78%
|
0.05
-17.86%
|
0.06
-12.50%
|
0.06
|
| EBIT |
|
-11.53
-20.28%
|
-9.59
-7.81%
|
-8.89
+31.70%
|
-13.02
|
| Net Income |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Pretax Income |
|
-11.44
-20.07%
|
-9.53
-7.53%
|
-8.86
+31.50%
|
-12.93
|
| Net Non Operating Interest Income Expense |
|
0.09
+55.17%
|
0.06
+87.10%
|
0.03
-62.65%
|
0.08
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
—
|
| Net Interest Income |
|
0.09
+55.17%
|
0.06
+87.10%
|
0.03
-62.65%
|
0.08
|
| Interest Expense |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
0.00
-100.00%
|
0.01
-51.72%
|
0.03
-78.83%
|
0.14
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Net Income From Continuing And Discontinued Operation |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Net Income Continuous Operations |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Normalized Income |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Net Income Common Stockholders |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Diluted EPS |
|
-0.25
+0.00%
|
-0.25
+19.35%
|
-0.31
+31.11%
|
-0.45
|
| Basic EPS |
|
-0.25
+0.00%
|
-0.25
+19.35%
|
-0.31
+31.11%
|
-0.45
|
| Basic Average Shares |
|
46.19
+22.68%
|
37.65
+29.79%
|
29.01
+0.69%
|
28.81
|
| Diluted Average Shares |
|
46.19
+22.68%
|
37.65
+29.79%
|
29.01
+0.69%
|
28.81
|
| Diluted NI Availto Com Stockholders |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Total Other Finance Cost |
|
-0.09
-55.17%
|
-0.06
-87.10%
|
-0.03
+62.65%
|
-0.08
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
11.77
|
| Current Assets |
|
11.26
|
| Cash Cash Equivalents And Short Term Investments |
|
11.02
|
| Cash And Cash Equivalents |
|
11.02
|
| Receivables |
|
0.00
|
| Accounts Receivable |
|
0.00
|
| Restricted Cash |
|
—
|
| Other Current Assets |
|
0.24
|
| Total Non Current Assets |
|
0.51
|
| Net PPE |
|
0.49
|
| Gross PPE |
|
0.49
|
| Other Properties |
|
0.49
|
| Non Current Deferred Assets |
|
0.01
|
| Non Current Deferred Taxes Assets |
|
0.01
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
1.38
|
| Current Liabilities |
|
1.09
|
| Payables And Accrued Expenses |
|
0.58
|
| Payables |
|
0.08
|
| Accounts Payable |
|
0.08
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
0.50
|
| Employee Benefits |
|
0.03
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.37
|
| Total Tax Payable |
|
—
|
| Income Tax Payable |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.13
|
| Current Capital Lease Obligation |
|
0.13
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.29
|
| Long Term Debt And Capital Lease Obligation |
|
0.26
|
| Long Term Capital Lease Obligation |
|
0.26
|
| Defined Pension Benefit |
|
0.01
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.03
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
10.39
|
| Common Stock Equity |
|
10.39
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
35.48
|
| Ordinary Shares Number |
|
35.48
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
114.73
|
| Retained Earnings |
|
-104.39
|
| Gains Losses Not Affecting Retained Earnings |
|
0.04
|
| Other Equity Adjustments |
|
0.04
|
| Total Equity Gross Minority Interest |
|
10.39
|
| Total Capitalization |
|
10.39
|
| Working Capital |
|
10.17
|
| Invested Capital |
|
10.39
|
| Total Debt |
|
0.39
|
| Capital Lease Obligations |
|
0.39
|
| Net Tangible Assets |
|
10.39
|
| Tangible Book Value |
|
10.39
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.37
-8.10%
|
-6.82
+6.73%
|
-7.31
+41.52%
|
-12.50
|
| Cash Flow From Continuing Operating Activities |
|
-7.37
-8.10%
|
-6.82
+6.73%
|
-7.31
+41.52%
|
-12.50
|
| Net Income From Continuing Operations |
|
-11.44
-19.89%
|
-9.54
-7.33%
|
-8.89
+31.99%
|
-13.07
|
| Depreciation Amortization Depletion |
|
0.03
-34.78%
|
0.05
-17.86%
|
0.06
-12.50%
|
0.06
|
| Depreciation |
|
0.03
-34.78%
|
0.05
-17.86%
|
0.06
-12.50%
|
0.06
|
| Depreciation And Amortization |
|
0.03
-34.78%
|
0.05
-17.86%
|
0.06
-12.50%
|
0.06
|
| Other Non Cash Items |
|
0.03
+740.00%
|
-0.01
|
—
|
-0.08
|
| Stock Based Compensation |
|
2.75
+7.59%
|
2.56
+51.33%
|
1.69
-24.83%
|
2.25
|
| Deferred Tax |
|
—
|
0.01
-51.72%
|
0.03
-83.33%
|
0.17
|
| Deferred Income Tax |
|
—
|
0.01
-51.72%
|
0.03
-83.33%
|
0.17
|
| Change In Working Capital |
|
1.26
+1022.32%
|
0.11
+157.44%
|
-0.20
+89.37%
|
-1.83
|
| Change In Receivables |
|
0.13
+200.00%
|
-0.13
-151.22%
|
0.25
+490.48%
|
-0.06
|
| Changes In Account Receivables |
|
0.13
+200.00%
|
-0.13
-151.22%
|
0.25
+490.48%
|
-0.06
|
| Change In Payables And Accrued Expense |
|
1.36
+439.68%
|
0.25
+150.70%
|
-0.50
+71.05%
|
-1.72
|
| Change In Accrued Expense |
|
1.04
+414.29%
|
0.20
+136.06%
|
-0.56
+64.09%
|
-1.57
|
| Change In Payable |
|
0.32
+544.90%
|
0.05
-25.76%
|
0.07
+144.30%
|
-0.15
|
| Change In Account Payable |
|
0.32
+544.90%
|
0.05
-25.76%
|
0.07
+144.30%
|
-0.15
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.01
|
| Change In Other Current Assets |
|
-0.23
-1535.71%
|
-0.01
-125.00%
|
0.06
+240.00%
|
-0.04
|
| Investing Cash Flow |
|
-0.11
-3466.67%
|
-0.00
+82.35%
|
-0.02
+83.33%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-0.11
-3466.67%
|
-0.00
+82.35%
|
-0.02
+83.33%
|
-0.10
|
| Net PPE Purchase And Sale |
|
-0.11
-3466.67%
|
-0.00
+82.35%
|
-0.02
+63.83%
|
-0.05
|
| Purchase Of PPE |
|
-0.11
-3466.67%
|
-0.00
+82.35%
|
-0.02
+63.83%
|
-0.05
|
| Capital Expenditure |
|
-0.11
-3466.67%
|
-0.00
+82.35%
|
-0.02
+63.83%
|
-0.05
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.06
|
| Financing Cash Flow |
|
13.71
+206.30%
|
4.48
-25.84%
|
6.04
+46330.77%
|
0.01
|
| Cash Flow From Continuing Financing Activities |
|
13.71
+206.30%
|
4.48
-25.84%
|
6.04
+46330.77%
|
0.01
|
| Net Common Stock Issuance |
|
13.44
+239.49%
|
3.96
-40.15%
|
6.62
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.53
-37.07%
|
0.84
|
0.00
-100.00%
|
0.01
|
| Net Other Financing Charges |
|
-0.26
+18.89%
|
-0.32
+44.31%
|
-0.58
|
—
|
| Changes In Cash |
|
6.27
+367.33%
|
-2.35
-81.64%
|
-1.29
+89.74%
|
-12.59
|
| Effect Of Exchange Rate Changes |
|
-0.04
|
0.00
|
—
|
—
|
| Beginning Cash Position |
|
8.74
-21.15%
|
11.09
-10.43%
|
12.38
-50.42%
|
24.96
|
| End Cash Position |
|
14.97
+71.32%
|
8.74
-21.15%
|
11.09
-10.43%
|
12.38
|
| Free Cash Flow |
|
-7.48
-9.62%
|
-6.82
+6.91%
|
-7.33
+41.60%
|
-12.55
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.17
|
| Common Stock Issuance |
|
13.44
+239.49%
|
3.96
-40.15%
|
6.62
|
0.00
|
| Issuance Of Capital Stock |
|
13.44
+239.49%
|
3.96
-40.15%
|
6.62
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-08 View
- 42026-05-08 View
- 42026-05-08 View
- 10-Q2026-05-08 View
- 8-K2026-05-08 View
- 8-K2026-04-03 View
- 10-K2026-03-27 View
- 8-K2026-03-27 View
- 42026-03-11 View
- 42026-03-09 View
- 8-K2026-03-04 View
- 42026-02-17 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-11 View
- 8-K2026-02-09 View
- 8-K2026-02-04 View
- 42026-01-02 View
- 42026-01-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|